# Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults

> **NCT03181074** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 10 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03181074
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-21
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181074, "Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03181074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*